Veredus launches VereMTB
Veredus Laboratories has launched VereMTB, a multiplexed molecular diagnostic chip capable of fast and accurate detection of mycobacterium tuberculosis complex (MTBC) and its mutations, as well as nine other clinically relevant non-tubercular mycobacterium, in Singapore. These mutations are responsible for resistance to multiple drugs and are contributing to the global spread of tuberculosis.
Conventional methods of accurately identifying TB infections can take up to eight weeks. In contrast, VereMTB can complete the diagnosis and identify the specific mycobacterium causing the infection and drug resistance in less than three hours from natural samples, avoiding the need for culturing, the most time-consuming part of the traditional method. Additionally due to its compact size, the system can be deployed in a wide range of settings at point-of-need.
The VereMTB multiplexed molecular diagnostic lab-on-chip was designed and tested through the TM-REST programme, as part of the European Commission's 7th Framework to develop new diagnostics to fight TB and malaria. Based on ST Microelectronics' lab-on-chip technology, the VereMTB chip is currently undergoing evaluations by the Chinese Center for Disease Control and Prevention in Beijing, China as part of their ongoing programme to assess new technologies for TB diagnostics.